The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers

Nilofer Azad, MD
Published Online: 7:21 PM, Sat November 11, 2017

Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.